CERT · Certara, Inc.

The thesis

Certara's cost-cutting recovery is gaining analyst support, but the shares now trade above the consensus price target, so the evidence still leans toward lagging the S&P 500 until the third-quarter report. That report, estimated for ~5 November 2026 and not yet confirmed by the company, must show realized savings from the roughly $13 million annual run-rate cost program announced on 4 August 2026 and keep 2026 continuing-operations guidance of $367–382 million revenue and $0.31–0.36 adjusted diluted earnings per share. Both figures are management projections until that report. Certara second-quarter release

Adjusted daily closes show the shares at $10.18 on 21 October 2026, up from $8.64 on 8 October 2026 and 35.6% higher over three months, and 20.0% below the 52-week high of $12.72. MarketBeat put the consensus target at $9.18 on 20 October 2026, with an average Hold rating from 12 analysts. The narrative is accelerating among analysts: TD Cowen raised its target to $11 on 13 October 2026 and KeyBanc raised its target to $12 on 16 October 2026. No new company report has come since 4 August 2026.

Bullish and bearish views on Certara, Inc.

The bull case on Certara, Inc. (CERT), in brief: Analyst targets are moving up. The bear case: Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $26.2 million, down 3%.

Bull case

• Analyst targets are moving up. KeyBanc kept an Overweight rating and raised its target to $12 from $9 in mid-October 2026. TD Cowen kept a Buy rating and raised its target to $11 from $9 on 13 October 2026, per MarketBeat.
• Software demand held in Q2. Certara reported second-quarter software revenue of $48.8 million, up 4% year over year, and software bookings of $50.7 million, up 9%, on 4 August 2026. Another bookings gain at the Q3 report would support the demand side of the case.
• Guidance was reaffirmed after the divestiture. On 4 August 2026 management kept 2026 continuing-operations revenue guidance at $367–382 million and adjusted EPS at $0.31–0.36, excluding the Regulatory and Medical Writing business sold in May 2026.
• Buybacks continue to be authorized. Certara said on 4 August 2026 that it had completed a $100 million repurchase program and its board had authorized another $50 million.
• A new AI partner is attached. Certara announced on 7 July 2026 a partnership with Nvidia to advance its open integrated AI platform, per Benzinga.

Bear case

• Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $26.2 million, down 3%.
• The price sits above consensus. The $10.18 close on 21 October 2026 is above MarketBeat's $9.18 consensus target of 20 October 2026, which reflects 1 Sell, 6 Hold, 4 Buy and 1 Strong Buy rating. UBS downgraded the shares to Neutral on 30 September 2026 with a $10 target, and Barclays stayed at Equal-Weight with a $9 target on 7 October 2026.
• Last quarter missed estimates. MarketBeat reported second-quarter adjusted EPS of $0.08 against $0.09 expected and revenue of $93.27 million against $98.09 million expected.
• Officer supply is visible. Leif E.
• The rebound is recent and sharp. The adjusted close rose from $8.64 on 8 October 2026 to $10.18 on 21 October 2026, with the earnings date still unconfirmed. MarketBeat reported a 6.6% intraday drop on 6 October 2026, so moves of this size have gone both ways in the past month.

Price setup

The last adjusted close is $10.18 (21 October 2026), 20.0% under the 52-week high of $12.72. The 14-day relative strength index is 58.8, a middling reading. MarketBeat reported on 20 October 2026 a 50-day moving average of $8.57 and a 200-day moving average of $7.01, so the shares sit well above both averages and the 50-day average is rising (it was $8.32 on 6 October 2026).

Analyst reference points cluster below the price. The consensus target is $9.18; UBS is at $10; TD Cowen at $11; KeyBanc at $12. Only the two most recent raises are above the close.

Crowding evidence that can be observed: a wide gap above a rising 50-day average, an earnings report expected in roughly two weeks, and a Form 144 officer sale filing from 3 September 2026. No retail-attention data is available for this dossier.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• ~5 November 2026, est.: third-quarter 2026 earnings release. Certara has not confirmed the date. The third-quarter 2025 report was on 6 November 2025 and the second-quarter 2026 report was on 4 August 2026. It tests realized savings from the cost program, services bookings and the reaffirmed guidance ranges. (passed 1d ago)
• Before the release: the company's date announcement. Certara announced its second-quarter date on 15 July 2026, about three weeks ahead. A third-quarter notice would fix the date. (passed 114d ago)

What would change the view

The case breaks if the third-quarter report shows services revenue or bookings falling again, no disclosed realized savings from the cost program, or guidance cut below $367 million revenue or $0.31 adjusted EPS. A close below $9.00 would also end it: that level sits just under MarketBeat's $9.18 consensus target and would reverse the October rebound.

The case strengthens if the report shows software bookings growing again, a quantified savings figure and unchanged or raised guidance. That would put the $11 and $12 targets from TD Cowen and KeyBanc within reach of the reported numbers.

What it trades with

Certara sells biosimulation software and scientific services to drug developers, so its demand follows pharmaceutical and biotech research budgets and regulatory-submission activity. Its 2026 guidance covers continuing operations only, after the May 2026 divestiture, so comparisons with earlier total-company figures are not like-for-like. No current theme cluster carries the name, and its recent moves have followed analyst actions and company-specific news.